Evidence map›Paper›PMID 40500748›Full record

Trial reportJournal of translational medicine2025

Injection of human umbilical cord mesenchymal stem cells exosomes for the treatment of knee osteoarthritis: from preclinical to clinical research.

Yuzhong Wang, Yajie Kong, Jiejie Du, Lifei Qi, Meiling Liu, Siyi Xie, Jianghui Hao, Ming Li, Shuxing Cao, Huixian Cui and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuzhong WangDepartment of Orthopedics, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, P. R. China.
Yajie KongDepartment of Orthopedics, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, P. R. China.ORCID 0009-0001-7650-4761
Jiejie DuHebei Taihe Yunshan Biotechnology Co., Ltd., Shijiazhuang, Hebei Province, P. R. China.
Lifei QiHebei Taihe Yunshan Biotechnology Co., Ltd., Shijiazhuang, Hebei Province, P. R. China.
Meiling LiuDepartment of Orthopedics, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, P. R. China.
Siyi XieDepartment of Orthopedics, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, P. R. China.
Jianghui HaoDepartment of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, P. R. China.
Ming LiDepartment of Orthopedics, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, P. R. China.
Shuxing CaoDepartment of Orthopedics, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, P. R. China.
Huixian CuiHebei Medical University-University of Galway Stem Cell Research Center, Hebei Medical University, Shijiazhuang, Hebei Province, 050017, P. R. China.
Aijing LiuHebei Medical University-University of Galway Stem Cell Research Center, Hebei Medical University, Shijiazhuang, Hebei Province, 050017, P. R. China. ajliu@hebmu.edu.cn.
Jun MaHebei Medical University-University of Galway Stem Cell Research Center, Hebei Medical University, Shijiazhuang, Hebei Province, 050017, P. R. China. junmahmu@hebmu.edu.cn.ORCID 0000-0003-2843-0769
Yongzhou SongDepartment of Orthopedics, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, P. R. China. yongzhousong@hebmu.edu.cn.

Funding

Hebei Province Key R&D Plan Project 22377752DHebei Provincial Medical Research Project 20210934Medical Science Research Project of Hebei Province 20230486Scientific Research Fund of the Second Hospital of Hebei Medical University 2HC202210
6 · The paper itself

Abstract

backgroundBackground: Exosomes (Exos) derived from mesenchymal stem cells (MSCs) share similar biological functions with MSCs but are more stable under various pathophysiological conditions, with a lower risk of immune rejection. Human umbilical cord mesenchymal stem cells (hUC-MSCs) are a promising source of MSC-derived exosomes (MSC-Exos), particularly for the treatment of osteoarthritis (OA), a degenerative joint disease characterized by inflammation and cartilage damage.

methodsIn this study, we conducted in vitro experiments on mouse articular chondrocytes and treated mouse OA models with hUC-MSCs-Exos. To validate the results of hUC-MSCs-Exos in humans, a randomized, double-blind, ascending dose study was conducted to investigate the safety and efficacy of hUC-MSCs-Exos in the treatment of OA, and human chondrocyte toxicity experiments were conducted prior to the clinical trial.

resultsIn this study, we successfully extracted hUC-MSCs and verified their multilineage differentiation ability in different culture media. We then verified the Exos morphology and the expression of CD9, CD63, TSG1, and CALN. In preclinical experiments in vitro and in vivo, we verified that hUC-MSC- Exos can reduce the inflammatory response of articular cartilage and promote its regeneration. Finally, clinical experiments confirmed that hUC-MSC- Exos injection treatment of OA patients did not cause any adverse consequences, and a certain degree of effectiveness was found in the comparison of clinical scores and MRI examinations before and after treatment.

conclusionsThis study shows that hUC-MSC-derived exosomes effectively reduce inflammation and promote cartilage regeneration in osteoarthritis, with demonstrated safety and efficacy in both preclinical and clinical settings.

trial registrationTrial No.MR-13-24-017929. Registered 11 February 2023, https://medicalresearch.org.cn/login# .

Indexed as

ExosomesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationOsteoarthritis, KneeUmbilical CordAnimalsCartilage, ArticularCell DifferentiationChondrocytesDisease Models, AnimalFemaleHumansInflammationMaleMiceMiddle AgedClinical researchExosomesHuman umbilical cord mesenchymal stem cellsOsteoarthritis

Identifiers

PMID40500748
PMCPMC12153132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.